IMMUNIC IMUX 深 沪
交易中 10-01 10:18:01 美东时间
8.903
-0.397
-4.27%
华盛通- 最 高9.44
- 今 开9.30
- 成交量 3.90万股
- 最 低 8.875
- 昨 收 9.30
- 总市值 1.21亿
- 52周最高 17.43
- 市盈率 静 --
- 换手率 0.29%
- 52周最低 5.062
- 委 比 -44.38%
- 总股本 1364.45万
- 历史最高 289.90
- 量 比 1.03
- 振 幅 6.08%
- 历史最低 5.062
- 每 手 1
- 风险率 3.26%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 齐声看好医药股！礼来、强生、默沙东目标价均获上调；小摩大幅上调Meta目标价至820美元
今日重点评级关注：康托·菲茨杰拉德：维持SOL Strategies"超配"评级，目标价从2.8美元升至6.2美元；康托·菲茨杰拉德：维持Sui Group Holdings"超配"评级，目标价从1.7美元升至3.4美元
09-11 14:30
HC Wainwright & Co. Reiterates Buy on Immunic, Maintains $22 Price Target
HC Wainwright & Co. analyst Matthew Caufield reiterates Immunic (NASDAQ:IMUX) with a Buy and maintains $22 price target.
09-10 18:13
Immunic Highlights Multiple Sclerosis Program in R&D Webinar
Immunic ( ($IMUX) ) just unveiled an announcement. On September 9, 2026, Immuni...
09-09 21:30
Immunic Appoints Chitrang Davé as Chief Data and Digital Officer
– New C-Suite Role and Appointment Underscore Commitment to Building a Strong, Commercial-Ready Data Ecosystem, in Preparation for Potential NDA Submission and Commercialization – NEW YORK, ...
09-01 18:30
美股大行评级 | 潜在涨幅455.56%！Cardiol Therapeutics获Canaccord Genuity上调目标价至10美元，维持"买入"评级
今日重点评级关注：Canaccord Genuity：维持Cardiol Therapeutics"买入"评级，目标价从8美元升至10美元；B. Riley证券：维持Macrogenics"买入"评级，目标价从9美元升至11美元
08-18 11:39
Wedbush Initiates Coverage On Immunic with Outperform Rating, Announces Price Target of $45
Wedbush analyst Martin Fan initiates coverage on Immunic (NASDAQ:IMUX) with a Outperform rating and announces Price Target of $45.
08-17 21:08
Immunic Q2 EPS $(0.80) Beats $(1.10) Estimate
Immunic (NASDAQ:IMUX) reported quarterly losses of $(0.80) per share which beat the analyst consensus estimate of $(1.10) by 27.27 percent. This is a 60 percent increase over losses of $(2.00) per share from the same period last year.
08-11 18:36
Immunic Appoints Elena Ridloff to Board of Directors
– Appointment Strengthens Board with Financial, Capital Markets and Commercial Leadership Expertise as the Company Approaches Pivotal Phase 3 ENSURE Readout in Relapsing Multiple Sclerosis a...
08-11 04:05
Immunic Names CEO Erik Lundgren to Board
Immunic ( ($IMUX) ) has issued an announcement. On June 29, 2026, Immunic direc...
07-07 04:45
